Patents by Inventor Peter A. Blomgren

Peter A. Blomgren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11897862
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Grant
    Filed: April 7, 2023
    Date of Patent: February 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
  • Publication number: 20230373950
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: March 15, 2023
    Publication date: November 23, 2023
    Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
  • Publication number: 20230295111
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 21, 2023
    Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
  • Patent number: 11739065
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: August 29, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20230242508
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: December 20, 2022
    Publication date: August 3, 2023
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Zhimin Du, Musong Kim, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani
  • Publication number: 20230158023
    Abstract: The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions.
    Type: Application
    Filed: November 18, 2022
    Publication date: May 25, 2023
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Jin-Ming Xiong, Jianjun Xu, Sundaramoorthi Swaminathan, Zhongdong Zhao
  • Patent number: 11578069
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: February 14, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn L. Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole A. Nava, Leena Patel, Jason K. Perry, Natalie Seeger, Kirk L. Stevens, Zhongdong Zhao
  • Publication number: 20230041518
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: July 19, 2021
    Publication date: February 9, 2023
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11517570
    Abstract: The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: December 6, 2022
    Assignee: Kronos Bio, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Sundaramoorthi Swaminathan, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao
  • Publication number: 20220242858
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: January 11, 2022
    Publication date: August 4, 2022
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20220226337
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: December 14, 2021
    Publication date: July 21, 2022
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Publication number: 20220204491
    Abstract: The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: November 24, 2021
    Publication date: June 30, 2022
    Inventors: Peter A. Blomgren, Kevin S. Currie, Morin Mae Frick, Elizabeth M. Horstman, Joshua A. Kaplan, Jeffrey E. Kropf, William J. Watkins
  • Publication number: 20220204460
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: November 29, 2021
    Publication date: June 30, 2022
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Publication number: 20220152014
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: October 22, 2021
    Publication date: May 19, 2022
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Publication number: 20220135561
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: October 13, 2021
    Publication date: May 5, 2022
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Publication number: 20220119383
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 21, 2022
    Inventors: Peter A. Blomgren, Taryn L. Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole A. Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer A. Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11247986
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 15, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Patent number: 11225473
    Abstract: The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Morin Mae Frick, Elizabeth M. Horstman, Joshua A. Kaplan, Jeffrey E. Kropf, William J. Watkins
  • Patent number: 11224600
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: January 18, 2022
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11179383
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: November 23, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao